MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
Why One CEO Thinks Drugs Won’t Be Able to Solve the Obesity Crisis
New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.
Hello Alpha, TrestleTree Partner To Support Weight Loss
In a new partnership, patients in need of weight loss support can receive primary care, mental health and chronic condition management through Hello Alpha. In between Hello Alpha visits, patients can access health coaching services from TrestleTree.
Twin Health Snags $50M to Help Employers, Health Plans Treat Metabolic Disease
Twin Health raked in $50 million in Series D financing. The startup seeks to help patients improve their metabolic health and reduce the need for medications through the “digital twin” technology it sells to employers and health plans.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Hims & Hers Gets Into Weight Loss Treatment
Hims & Hers unveiled a new weight loss program on Monday that includes access to medications, educational content and digital tracking tools.
Weight Loss Startup Calibrate Is Changing Hands
Weight loss company Calibrate — which sells a program combining GLP-1 drugs with personalized metabolic health coaching — announced a legal restructuring of its business. The startup, which recently had two major rounds of layoffs, has struggled amid GLP-1 drug shortages and mounting user complaints.
Structure Raises $300M as Oral GLP-1 Drug’s Data Keep Up With Pfizer, Eli Lilly
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
WeightWatchers To Acquire Chronic Weight Management Digital Health Platform
WeightWatchers will acquire Sequence, a platform that allows patients to have virtual appointments with a clinician, gives access to a dietitian and fitness coaching and provides prescription medications, including Ozempic and Wegovy. The deal is anticipated to close during the second quarter of 2023, and WeightWatchers will pay the net purchase price of $106 million.
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
Obesity is a disease—and it’s treatable
Obesity is a disease, and America’s healthcare providers and hospital systems must be part of changing how we treat it. That means many of us in the health ecosystem must reexamine how we view patients with excess weight.
America’s obesity epidemic requires action, not posturing
Pinterest's move to outright ban all ads referring to weight loss — regardless of quality of information — is woefully misguided, writes a former Pinterest executive.
Lark Health shows impact of its diabetes prevention program on older patients
Among the 360 participants over the age of 50 in the study, the company was able to drive an average of 4.3 percent body weight loss, which works out to an average of 4.4 kgs.